Filing Flows › Arbutus Biopharma (ABUS) › Q1 2026 › vs Q4 2025
Arbutus Biopharma (ABUS) Q1 2026 vs Q4 2025 (quarter over quarter)
Arbutus Biopharma's revenue rose $178M (170×) from $1.1M in Q4 2025 to $179M in Q1 2026. Operating margin 94.3% against -503.3% (+597.6 pts).
Arbutus Biopharma, Q1 2026: revenue $179M (102× year over year), operating margin 94.3%, net earnings $170M, operating cash flow −$8.1M. The chart draws each line against Q4 2025, the increases inside each band.
Margins
| Q1 2026 | Q4 2025 | Change | |
|---|---|---|---|
| Operating margin | 94.3% | -503.3% | +597.6 pts |
| Net margin | 94.7% | -357.4% | +452.1 pts |
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $179M | $1.1M | $178M | 170× |
| Other income, net | $787K | $1.5M | −$747K | -49% |
| Operating profit | $169M | −$5.3M | $174M | — |
| Costs & expenses | $10.2M | $6.3M | $3.9M | +61% |
| Pre-tax earnings | $170M | −$3.8M | $173M | — |
| Net earnings | $170M | −$3.8M | $173M | — |
| Operating cash sources | $179M | $2.2M | $177M | 82× |
| Depreciation & amortization | $11K | $11K | $0 | 0% |
| Share-based compensation | $1.4M | $1.3M | $97K | +8% |
| Cash used in operations | $8.1M | $4.7M | $3.4M | +73% |
| Working capital & other | $179M | $2.2M | $177M | 82× |
Questions
How much did Arbutus Biopharma's revenue grow quarter over quarter in Q1 2026?
Arbutus Biopharma's revenue rose $178M (170×) from $1.1M in Q4 2025 to $179M in Q1 2026. Operating margin 94.3% against -503.3% (+597.6 pts).